Table 1.
Clinical and demographical features of our four patients
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age | 75 | 53 | 77 | 59 |
| Sex | Female | Male | Male | Male |
| Patient history | ||||
| Pre-stroke mRS (0-5) | 0 | 0 | 0 | 0 |
| Comorbidities | AF, CKD, hypertension, hypercholesterolemia, obesity, | Hypertension, hypercholesterolemia | Diabetes | Smoking, biological aortic valve prosthesis, endocarditis |
| Antiplatelet/anticoagulant | No | No | No | Antiplatelet |
| COVID − 19 characteristics | ||||
| Nasopharyngeal swab | Positive | Positive | / | Positive |
| Chest CT | Negative | Ground-glass opacities | Ground-glass opacities | Ground-glass opacities |
| Fever | Yes | No | Yes | Before the admission |
| Cough | Yes | 3 weeks before the admission | No | A few days before the admission |
| Dyspnoea | Yes | No | Yes | Yes |
| Myalgia | No | 3 weeks before the admission | No | No |
| Gastrointestinal symptoms | No | No | No | No |
| Days from COVID-19 diagnosis to stroke onset | 0 | 0 | 0 | 0 |
| Pharmacological treatment | Darunavir, piperacillin/tazobactam | Hydroxychloroquine, ceftriaxone + azithromycin | Hydroxychloroquine | Hydroxychloroquine, kaletra, LMWH, vancomycin + gentamicin, ampicillin + ceftriaxone |
| Oxygen therapy | High-flow | No | Low-flow | Low-flow |
| Laboratory findings | ||||
| Glucose mg/dl | 144 | 190 | 362 | 133 |
| Creatinine mg/dl | 2,84 | 0,90 | 1,04 | 0,9 |
| INR | 1,16 | 0,99 | 1,05 | 0,79 |
| Platelets × 10^9/L | 182 | 251 | 132 | 197 |
| Haemoglobin g/dl | 11,40 | 15,1 | 13,2 | 11,7 |
| Leucocytes × 10^9/L | 6,8 | 7,3 | 7,5 | 21,5 |
| Lymphocytes × 10^9/L | 0,66 | 1,6 | 1,23 | 0,92 |
| Neutrophils × 10^9/L | 5,54 | 4,8 | 5,66 | 19,48 |
| LDH U/L | 492 | 187 | / | 705 |
| CPK U/L | 162 | 79 | 123 | / |
| Troponin pg/ml | / | < 15 | 1090 | 2380 |
| aPTT seconds | / | 32 | 36 | 38 |
| CRP mg/l | 19,4 | 2,9 | 4,4 | 221 |
| D-dimer mcg/ml | / | 313 | / | 112,229 |
| Fibrinogen | / | 323 | 305 | / |
| Ferritin microg/l | / | 89 | / | 1907 |
| IL6 pg/ml | / | / | / | / |
| Stroke features | ||||
| Clinical symptoms | Global aphasia and right hemiparesis | Left sensorimotor hemisyndrome | Global aphasia and mild right hemiparesis | Global aphasia |
| NIHSS at baseline | 8 | 5 | 10 | 9 |
| NIHSS after 24 h | 7 | 1 | 20 | 0 |
| Haemorrhagic transformation | Yes | No | Yes | Yes |
| Modified TOAST | Cardioembolic | Unknown | LAA | Cardioembolic (endocarditis) |
| Large vessel occlusion | No | No | No | No |
| Complications | Respiratory insufficiency | None | Myocardial infarction | Cardiac arrest |
| Outcome | Death | Complete clinical recovery | Death | Death |
/ means that we don't have this parameter